ProMIS Neurosciences Inc: Results Will Inform Dosing of Phase 1B Clinical Trial in Alzheimer's Patients, Which Is on Track to Initiate in H2
ProMIS Neurosciences公司:結果將有助於用藥量確定阿爾茨海默病患者的10億臨床試驗,該試驗計劃於下半年開始。
ProMIS Neurosciences Inc: Results Will Inform Dosing of Phase 1B Clinical Trial in Alzheimer's Patients, Which Is on Track to Initiate in H2
ProMIS Neurosciences公司:結果將有助於用藥量確定阿爾茨海默病患者的10億臨床試驗,該試驗計劃於下半年開始。
譯文內容由第三人軟體翻譯。